MyoKardia to Present at 40th Annual Cowen Health Care Conference
February 24, 2020 08:00 ET
|
MyoKardia, Inc.
BRISBANE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care...
MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
February 20, 2020 08:00 ET
|
MyoKardia, Inc.
BRISBANE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday,...
MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 08:00 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 38th Annual J.P....
MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference
November 27, 2019 08:00 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at...
MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
November 11, 2019 07:30 ET
|
MyoKardia, Inc.
Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo...
MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten
November 11, 2019 07:30 ET
|
MyoKardia, Inc.
Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s...
MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference
November 06, 2019 16:05 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at...
MyoKardia Reports Third Quarter 2019 Financial Results
November 04, 2019 16:44 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the...
MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019
November 04, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA)...
MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population
October 28, 2019 08:30 ET
|
MyoKardia, Inc.
Interim Data Demonstrated Favorable Safety and Activity Profile in Phase 2a Multiple-Ascending Dose Study Phase 2 Clinical Trial in Targeted Segment of Genetic DCM to Initiate in 1H 2020 SOUTH SAN...